CopyFind
Medicine 📍 BR

ACETATO DE ABIRATERONA

13 440,96 R$

Max. consumer price (CMED)

Analogs of ACETATO DE ABIRATERONA

Find cheaper analogs and generic equivalents for ACETATO DE ABIRATERONA.

Ingredients

Active Ingredient: abiraterone acetate


Product Overview

About ACETATO DE ABIRATERONA

ACETATO DE ABIRATERONA is a medication containing the active ingredient abiraterone acetate. Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).

Key Benefits & Uses

  • Used for: 1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic.
  • Use only as directed on the product label or by a healthcare professional.
  • Follow the authorised product information for dosing and duration of use.

Active Ingredient & Action

abiraterone acetate, the active ingredient in ACETATO DE ABIRATERONA, is the pharmacologically active substance of this product. 1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablet is a CYP17 inhibitor indicated in. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking ACETATO DE ABIRATERONA. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use ACETATO DE ABIRATERONA for extended periods without medical advice.

Visitor ratings

Help others by rating how useful this product page is.

No ratings yet — be the first.